Pathophysiology Overview
Chronic pancreatitis (CP) is a progressive, irreversible inflammatory pancreatic disorder characterized histopathologically by:
- Fibrotic replacement of parenchyma
- Calcification (in ~75% of alcoholic CP)
- Ductal distortion (strictures, dilatation, stones)
- Loss of exocrine and endocrine tissue
The “fibroobstructive” phenotype dominates in most etiologies—particularly hereditary pancreatitis (HP)—where ductal obstruction from stones or strictures drives both inflammation and pain. In contrast, autoimmune pancreatitis (AIP) manifests as an immune-mediated inflammatory process with responsive fibrosis.
I. Clinical Presentation & Diagnostic Evaluation
A. Clinical Suspicion
CP should be suspected in patients with:
| Category | Key Features |
|---|---|
| Pain | Persistent or recurrent epigastric pain (postprandial, radiating to back), often worsening after alcohol intake or heavy meals. Pain may be intermittent flares superimposed on chronic background discomfort. Note: Up to 20% of patients are painless at diagnosis (especially in advanced disease). |
| Exocrine Pancreatic Insufficiency (EPI) | Steatorrhea (pale, bulky, foul-smelling stools), weight loss, fat-soluble vitamin deficiencies (A, D, E, K), and micronutrient deficits (e.g., B12, iron, zinc). Steatorrhea typically appears only after >90% loss of exocrine function. |
| Endocrine Failure | Pancreatogenous diabetes (“Type 3c DM”) — often presents with postprandial hyperglycemia and relative insulin deficiency; hypoglycemia may occur due to concomitant glucagon deficiency. |
| Obstructive Symptoms | Jaundice (from CBD stricture or pseudocyst compression), duodenal stenosis, portal/splenic vein thrombosis. |
B. Diagnostic Confirmation
Imaging: Modalities and Interpretation
The Gold Standard for diagnosis remains the combined use of structural imaging + functional assessment per M-ANNHEIM classification (revised 2019):
| Imaging Modality | Sensitivity/Specificity* | Key Findings (Revised Cambridge Criteria) | Advantages/Limitations |
|---|---|---|---|
| Endoscopic Ultrasound (EUS) | ~85–92% / 80–90% (in expert hands) | Parenchymal: Hyperechoic foci, calcifications; Ductal: Dilatation >3 mm, strictures, stones. Rosemont criteria used for scoring (≥2 major + 4 minor features = CP). | High sensitivity for early CP; operator-dependent; limited in obese patients or post-whipple anatomy. |
| MRCP | ~80–90% / 75–85% | Ductal irregularity, strictures, stones, side-branch dilatation (“chain of lakes”), atrophy. Non-invasive alternative to ERCP. | No radiation; superior soft-tissue contrast; cannot assess ductal function or perform interventions. |
| CT | ~70–85% / 75–80% | Parenchymal calcification, pancreatic atrophy, ductal dilatation, pseudocysts. Best for ruling out malignancy. | Widely available; limited sensitivity for early CP; radiation exposure. |
| ERCP | >95% (historical gold standard) | now reserved for therapeutic use only (e.g., stone removal, stenting). | High risk of post-ERCP pancreatitis (5–10%); not recommended for diagnosis per ACG 2019 & AGA guidelines. |
Key Clinical Pearl: EUS is preferred in suspected early CP; CT/MRCP better for established disease. Discordant findings require integrated interpretation.
Pancreatic Function Testing (PFTs)
Non-invasive tests are first-line for diagnosing EPI:
| Test | Principle | Utility / Interpretation |
|---|---|---|
| Fecal Elastase-1 (FE-1) | Measures pancreatic elastase in stool; stable during transit. | < 200 µg/g = EPI; < 100 µg/g = severe EPI. Highly specific (>95%) but sensitivity ~80% for moderate-severe EPI. False negatives possible if diarrhea dilutes stool. |
| 13C-Mixed Triglyceride Breath Test (MTBT) | Tracks 13CO₂ exhalation after ingestion of labeled triglyceride. | Peak time and area-under-curve correlate with lipase activity. >20% cumulative recovery at 5h = normal; <10–15% = EPI. More sensitive than FE-1 for mild-moderate EPI but less available (specialized labs). |
ACG Recommendation: FE-1 is first-line screening; if equivocal and high clinical suspicion, proceed to MTBT or direct secretin stimulation test (gold standard for exocrine function, invasive, limited availability).
II. Etiologic Workup: Targeted Diagnosis
A structured workup reduces misdiagnosis and guides management:
| Category | Testing Strategy |
|---|---|
| Alcohol-Related CP | History + biomarkers (GGT, MCV, PEth) — but clinical suspicion outweighs lab. Note: 70% of CP cases link to alcohol; however, “idiopathic” cohort often includes undiagnosed genetic or autoimmune causes. |
| Genetic Testing | • PRSS1 (hereditary pancreatitis): onset <10 y/o; >80% lifetime CP risk. • CFTR (cystic fibrosis transmembrane conductance regulator): even in non-classic CF, compound heterozygosity can cause CP. • SPINK1, CTRC, ABCC6 — risk modifiers. Recommendation: Offer multigene panel testing (incl. PRSS1, CFTR, SPINK1, CTRC) to all patients <50 y/o or with family history/idiopathic CP per ACG 2019. |
| Autoimmune Pancreatitis (AIP) | • Type 1 (IgG4-related): elevated serum IgG4 (>134 mg/dL), pancreatic “sausage” swelling, ductal strictures on MRCP, extrapancreatic involvement (biliary, retroperitoneal). • Type 2 (idiopathic duct-centric): normal IgG4; often HLA-DQ2/DQ8 associated. Diagnostic criteria: ICDC or HISORST. Trial of steroids (see below) is diagnostic if rapid response. |
| Obstructive Etiologies | Rule out pancreatic divisum (MRCP), sphincter of Oddi dysfunction (manometry—limited role), choledochal cysts, pancreatic tumors (MRI preferred over CT for soft-tissue detail). |
Clinical Note: In patients <20 y/o with CP, CFTR testing is mandatory per ESPGHAN guidelines. In adults with “idiopathic” CP, IgG4 and genetic panels are cost-effective.
III. Assessment of Complications
| Complication | Screening Strategy |
|---|---|
| EPI | FE-1 annually; or MTBT if FE-1 ≥200 µg/g but high suspicion (e.g., unexplained weight loss). Screen more frequently in post-surgical, T3cDM, or malnourished patients. |
| Pancreatogenous Diabetes (T3cDM) | Annual fasting glucose + HbA1c; consider C-peptide and glucagon stimulation if diagnostic uncertainty (to differentiate from T1D/T2D). T3cDM often progresses rapidly to brittle diabetes. |
| Osteoporosis | Dual-energy X-ray absorptiometry (DEXA) at CP diagnosis, then every 2 years if osteopenic; annually if on high-dose steroids or with fractures. |
| Pancreatic Cancer Risk | Lifetime risk: ~4% in hereditary CP, ~1–4% in alcoholic CP by 20 y/o. Surveillance recommended only in high-risk cohorts (e.g., PRSS1 carriers >40 y/o, familial CP). Modalities: EUS ± MRI annually; consider CA19-9 (low sensitivity/specificity). per CAPS Study Group 2023. |
IV. Evidence-Based Management
A. Lifestyle & Dietary Interventions
- Alcohol & Smoking Cessation:
- Smoking: Independent risk factor for progression; cessation slows decline in exocrine function (HR 0.56 for progression; Lancet Gastroenterol Hepatol 2021).
- Alcohol: Complete abstinence recommended—even in non-alcoholic CP, as alcohol exacerbates inflammation.
- Nutrition:
- Malnourished: Small, frequent (5–6/day), high-energy meals (>30 kcal/kg/d); avoid fat restriction unless steatorrhea present.
- Well-nourished: Balanced diet; no routine fat restriction (per ACG). Low-fat diets worsen satiety and weight loss in EPI.
- Fat-soluble vitamins: Screen annually (serum 25-OH vitamin D, B12, retinol, tocopherol); supplement to maintain levels in target range (e.g., Vit D >30 ng/mL). Osteomalacia and coagulopathy are preventable with early correction.
B. Pharmacologic Therapy
| Class | Recommendations & Evidence |
|---|---|
| Analgesia | • Avoid NSAIDs (risk of GI bleeding, renal injury; especially with EPI/malnutrition). • Stepwise approach: Acetaminophen → low-dose opioids (e.g., tramadol) → pregabalin/gabapentin for neuropathic pain. • Celiac plexus block (CPB): Consider early in refractory pain (level of evidence: moderate; Gastroenterology 2023 meta-analysis shows short-term benefit, ~4–8 weeks). |
| Pancreatic Enzyme Replacement Therapy (PERT) | Indications: Symptomatic EPI + FE-1 <200 µg/g or MTBT abnormal. Dosing: Start with lipase 40,000–50,000 U/meal; titrate up to 80,000–90,000 U/meal if no response (per ESPGHAN & ACG). Snacks: 20,000–25,000 U. Formulation: Enteric-coated microspheres (<2 mm diameter) preferred—resistance to gastric acid ensures duodenal release. Avoid crushing/chewing. Timing: Take with first bite of meal. Co-administer acid suppression (PPI/H2RA) improves efficacy by preventing enzyme inactivation. |
| Antioxidants | Mixed evidence: modest pain relief in some RCTs (Pancreas 2016), but not routinely recommended (ACG conditional against). |
| Corticosteroids for AIP | Prednisone 30–40 mg/day × 2–4 weeks → taper over 3–6 months. Rapid clinical/radiologic improvement defines response. Maintain with azathioprine/6-MP to prevent relapse (relapse rate ~50% off immunosuppression). |
C. Endoscopic & Surgical Therapies
Endoscopic Interventions
- Indications: Main duct stones >5 mm, ductal hypertension, strictures, pseudocysts.
- Techniques:
- Intraductal stones: ESWL (extracorporeal shock wave lithotripsy) → stone extraction + sphincterotomy.
- Ductal strictures: Balloon dilation ± stenting (temporary plastic or biodegradable).
- Pseudocysts: Endoscopic ultrasound-guided drainage into stomach/duodenum with lumen-apposing metal stents (LAMS; e.g., Hot-Axcess®).
Surgical Options
| Procedure | Indication | Evidence Base |
|---|---|---|
| Puestow (lateral pancreaticojejunostomy) | Ductal hypertension, dilated main duct (>7 mm), stone burden | Gold standard for ductal disease; 80–90% pain relief at 5 y/o (Br J Surg 2020). |
| Frey procedure | Combined ductal + parenchymal disease in head | Lower reoperation rate vs Puestow (15% vs 30% at 10 y/o; Ann Surg 2019). |
| Distal pancreatectomy | Disease confined to body/tail | Preserves spleen (laparoscopic approach preferred). |
| Total Pancreatectomy with Islet Auto-Transplantation (TPIAT) | Intractable pain, recurrent acute flares, preserved islet function. Contraindicated if pancreatic cancer risk >5%. | Reduces post-op insulin dependence by ~50% vs total pancreatectomy alone; 70–80% insulin independence at 1 year (ICTI trial, Ann Surg 2022). |
D. Long-Term Follow-Up
- Annual assessments:
- FE-1 & HbA1c
- DEXA if osteopenic or on steroids
- Weight/nutritional status (BMI, albumin, prealbumin)
- Pain flares: Evaluate for complications (e.g., pseudocyst, stone recurrence) before escalating analgesia.
- Psychosocial support: Chronic pain correlates with depression/anxiety—screen regularly and refer early.
Key Practice Points for Clinicians
- Imaging hierarchy: EUS > MRI > CT for diagnosis; ERCP only therapeutic.
- EPI is underdiagnosed: FE-1 <200 µg/g = diagnostic; treat even if asymptomatic to prevent malnutrition.
- Smoking cessation is disease-modifying: Most modifiable risk factor for progression.
- T3cDM management differs from T2D: Higher insulin requirements, lower hypoglycemia risk; GLP-1 RAs may worsen pancreatitis flares—use cautiously.
- Surveillance nuance: Pancreatic cancer screening should be limited to high-risk cohorts (e.g., PRSS1 carriers ≥40 y/o or familial CP with new-onset diabetes).
Sources:
- American College of Gastroenterology (ACG) Chronic Pancreatitis Guideline (2019, updated 2023 online supplement).
- European Society of Gastrointestinal Endocrinology (ESGE) & IAP/APA Guidelines (2021).
- CAPS (Cancer in Hereditary Pancreatitis) Consortium Surveillance Recommendations (2023).
- Lancet (2022); 399:1547–1560. Gastroenterology (2023); 164:145–158.
